Magnesium Isoglycyrrhizinate Attenuates Anti-Tuberculosis Drug-Induced Liver Injury by Enhancing Intestinal Barrier Function and Inhibiting the LPS/TLRs/NF-κB Signaling Pathway in Mice

Liver injury caused by first-line anti-tuberculosis (anti-TB) drugs accounts for a high proportion of drug-induced liver injury (DILI), and gut microbiota and intestinal barrier integrity have been shown to be involved in the development of DILI. Magnesium isoglycyrrhizinate (MgIG) is the fourth-generation glycyrrhizic acid preparation, which is well documented to be effective against anti-TB DILI, but the underlying mechanism is largely unclear. In the present study, we established a BALB/c mice animal model of the HRZE regimen (39 mg/kg isoniazid (H), 77 mg/kg rifampicin (R), 195 mg/kg pyrazinamide (Z), and 156 mg/kg ethambutol (E))-induced liver injury to investigate the protective effect of MgIG against anti-TB DILI and underlying mechanisms. The results demonstrated that intraperitoneal injection of MgIG (40 mg/kg) significantly ameliorated HRZE-induced liver injury by reducing alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (AKP), and malondialdehyde (MDA) levels and improved liver pathological changes. Species composition analysis of gut microbiota showed that Lactobacillus was the only probiotic that was down-regulated by HRZE and recovered by MgIG. In addition, MgIG attenuated HRZE-induced intestinal pathology, significantly decreased HRZE-induced intestinal permeability by increasing the protein expression of tight junction protein 1 (ZO-1) and occludin, decreased HRZE-induced high lipopolysaccharide (LPS) levels, and further markedly attenuated mRNA expression levels of TNF-α, IL-6, TLR2, TLR4, and NF-κB. Supplementation with Lactobacillus rhamnosus JYLR-005 (>109 CFU/day/mouse) alleviated HRZE-induced liver injury and inflammation in mice. In summary, MgIG effectively ameliorated HRZE-induced liver injury by restoring the abundance of Lactobacillus, enhancing intestinal barrier function, and further inhibiting the activation of the LPS/TLRs/NF-κB signaling pathway. Regulating gut microbiota and promoting the integrity of intestinal barrier function may become a new direction for the prevention and treatment of anti-TB DILI.

[1]  D. J. Kim,et al.  The Lactobacillus as a Probiotic: Focusing on Liver Diseases , 2022, Microorganisms.

[2]  Mou-Ze Liu,et al.  Comparative effectiveness of glycyrrhizic acid preparations aimed at preventing and treating anti-tuberculosis drug-induced liver injury: A network meta-analysis of 97 randomized controlled trials. , 2022, Phytomedicine : international journal of phytotherapy and phytopharmacology.

[3]  D. He,et al.  An Investigation of the Risk Factors Associated With Anti-Tuberculosis Drug-Induced Liver Injury or Abnormal Liver Functioning in 757 Patients With Pulmonary Tuberculosis , 2021, Frontiers in Pharmacology.

[4]  E. Hara,et al.  Gut‐liver axis‐mediated mechanism of liver cancer: A special focus on the role of gut microbiota , 2021, Cancer science.

[5]  G. Davies,et al.  The Treatment of Tuberculosis , 2021, Clinical pharmacology and therapeutics.

[6]  Baoming Tian,et al.  Lycium ruthenicum anthocyanins attenuate high-fat diet-induced colonic barrier dysfunction and inflammation in mice by modulating the gut microbiota. , 2021, Molecular nutrition & food research.

[7]  Jinghan Li,et al.  Magnesium Isoglycyrrhizinate Alleviates Arsenic Trioxide-Induced Cardiotoxicity: Contribution of Nrf2 and TLR4/NF-κB Signaling Pathway , 2021, Drug design, development and therapy.

[8]  Yujun Liu,et al.  Lactobacillus plantarum Y44 alleviates oxidative stress by regulating gut microbiota and colonic barrier function in Balb/C mice with subcutaneous D-galactose injection. , 2020, Food & function.

[9]  R. Teschke,et al.  Mechanism of idiosyncratic drug induced liver injury (DILI): unresolved basic issues , 2020, Annals of translational medicine.

[10]  Lanjuan Li,et al.  Protective effect of Lactobacillus salivarius Li01 on thioacetamide‐induced acute liver injury and hyperammonaemia , 2020, Microbial biotechnology.

[11]  A. Grakoui,et al.  Contribution of the Intestinal Microbiome and Gut Barrier to Hepatic Disorders. , 2020, Gastroenterology.

[12]  Peng Chen,et al.  [Gut microbiota-an important contributor to liver diseases]. , 2020, Nan fang yi ke da xue xue bao = Journal of Southern Medical University.

[13]  A. de Gottardi,et al.  The gut-liver axis in liver disease: pathophysiological basis for therapy. , 2020, Journal of hepatology.

[14]  S. Lim,et al.  Drug induced liver injury: East versus West – a systematic review and meta-analysis , 2019, Clinical and molecular hepatology.

[15]  H. Bai,et al.  Association of LEPR polymorphisms with predisposition and inflammatory response in anti-tuberculosis drug-induced liver injury: A pilot prospective investigation in Western Chinese Han population. , 2019, Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases.

[16]  P. Watkins,et al.  Drug-induced liver injury , 2019, Nature Reviews Disease Primers.

[17]  Hao Xu,et al.  The administration of Escherichia coli Nissle 1917 ameliorates irinotecan-induced intestinal barrier dysfunction and gut microbial dysbiosis in mice. , 2019, Life sciences.

[18]  Hang Shi,et al.  Protective Effects of Magnesium Glycyrrhizinate on Methotrexate-Induced Hepatotoxicity and Intestinal Toxicity May Be by Reducing COX-2 , 2019, Front. Pharmacol..

[19]  Shan-shan Geng,et al.  Magnesium isoglycyrrhizinate suppresses LPS-induced inflammation and oxidative stress through inhibiting NF-κB and MAPK pathways in RAW264.7 cells. , 2019, Bioorganic & medicinal chemistry.

[20]  Liuqing Di,et al.  Glycyrrhizic acid improving the liver protective effect by restoring the composition of Lactobacillus , 2019, Journal of Functional Foods.

[21]  L. L. Nwidu,et al.  Telfairia occidentalis (Cucurbitaceae) pulp extract mitigates rifampicin-isoniazid-induced hepatotoxicity in an in vivo rat model of oxidative stress. , 2019, Journal of integrative medicine.

[22]  Wei Wang,et al.  Magnesium isoglycyrrhizinate attenuates D-galactosamine/lipopolysaccharides induced acute liver injury of rat via regulation of the p38-MAPK and NF-κB signaling pathways , 2018, Immunopharmacology and immunotoxicology.

[23]  Xia Wang,et al.  Amelioration of Ethanol-Induced Hepatitis by Magnesium Isoglycyrrhizinate through Inhibition of Neutrophil Cell Infiltration and Oxidative Damage , 2017, Mediators of inflammation.

[24]  Hong Zhang,et al.  Pyrrolidine dithiocarbamate alleviates the anti-tuberculosis drug-induced liver injury through JAK2/STAT3 signaling pathway: An experimental study. , 2017, Asian Pacific journal of tropical medicine.

[25]  Yilin Yang,et al.  Diallyl trisulfide protects the liver against hepatotoxicity induced by isoniazid and rifampin in mice by reducing oxidative stress and activating Kupffer cells. , 2016, Toxicology research.

[26]  Shan-shan Geng,et al.  Anti-inflammatory Activity of Magnesium Isoglycyrrhizinate Through Inhibition of Phospholipase A2/Arachidonic Acid Pathway , 2015, Inflammation.

[27]  Y. Cao,et al.  Comparison of the Exposure of Glycyrrhizin and its Metabolites and the Pseudoaldosteronism after Intravenous Administration of Alpha- and Beta-glycyrrhizin in Rat , 2013, Drug Research.

[28]  A. Boumendjel,et al.  Green tea extract alleviates arsenic-induced biochemical toxicity and lipid peroxidation in rats , 2013, Toxicology and industrial health.

[29]  Mihai Pop,et al.  Metastats: an improved statistical method for analysis of metagenomic data , 2011, Genome Biology.

[30]  E. Porat,et al.  Toll-like receptor 4 stimulation initiates an inflammatory response that decreases cardiomyocyte contractility. , 2011, Antioxidants & redox signaling.

[31]  C. Huttenhower,et al.  Metagenomic biomarker discovery and explanation , 2011, Genome Biology.

[32]  William A. Walters,et al.  QIIME allows analysis of high-throughput community sequencing data , 2010, Nature Methods.